24 June 2025NewsAmericasSarah Speight

A step too far? Why Stewart’s approach is dividing opinion

Coke Morgan Stewart has issued a raft of decisions under new guidance intended to improve the US patent appeals board process. But it’s a divisive issue, finds Sarah Speight.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'

12 June 2025 Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record.

Americas

USPTO’s Stewart: Don’t nix patents as penalty for misconduct

10 June 2025 Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.

Big Pharma

‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal

5 June 2025 Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the dos and don’ts of protection from senior counsel.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

A step too far? Why Stewart’s approach is dividing opinion

More on this story

Editor's picks

Editor's picks

More features